Centre Hospitalier du Mans

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

Alain Combes, David Hajage, Gilles Capellier et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Placebo-controlled Phase 3, Maintenance Treatment, Medicine +7

High versus Low Blood-Pressure Target in Patients with Septic Shock

Pierre Asfar, Ferhat Meziani, Jean‐François Hamel et al. · New England Journal of Medicine · 2014 · 1.2K citations · Full text

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 965 citations

Medicine, Pathology, Pleural Disease +5